文献速递流行病学与生物统计临床试验与 GCP

焦虑障碍、强迫症和创伤后应激障碍患者停用抗抑郁药后的复发风险:复发预防试验的系统综述与Meta分析

Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials.
PubMed 文献 · BMJ · 2017-09-13

该系统综述与Meta分析纳入28项复发预防试验(n=5233),比较焦虑障碍患者抗抑郁药继续治疗与停药后的复发风险,最长随访1年。停药较继续治疗增加复发 odds(汇总OR 3.11,95%CI 2.48至3.89),复发时间更短(汇总HR 3.63,95%CI 2.58至5.10),安慰剂组复发率36.4% vs 抗抑郁药组16.4%。

要点

  • 停药较继续抗抑郁药治疗增加复发 odds(汇总 OR 3.11,95%CI 2.48 至 3.89)。
  • 停药后复发时间更短(汇总 HR 3.63,95%CI 2.58 至 5.10;11 项研究)。
  • 安慰剂组复发率 36.4% vs 抗抑郁药组 16.4%,但各研究间变异大。

核心结论

  • 在最长1年随访内,与继续治疗相比,停用抗抑郁药导致应答者复发率更高。
  • 缺乏1年之后的证据不应被解释为明确建议在1年后停用抗抑郁药。
  • 鉴于焦虑障碍的慢性性,治疗应由长期考虑指导,包括复发率、副作用和患者偏好。

研究设计与样本

  • 系统综述与复发预防试验的Meta分析。
  • 检索PubMed、Cochrane、Embase和临床试验注册库(从建库至2016年7月)。
  • 纳入对抗抑郁药应答的焦虑障碍患者,随机双盲继续抗抑郁药或换用安慰剂,比较复发率或复发时间。
  • 共纳入28项研究(n=5233),最长随访1年;偏倚风险总体评为低。

主要发现

  • 停药较继续抗抑郁药增加复发 odds(汇总 OR 3.11,95%CI 2.48 至 3.89)。
  • 亚组分析与Meta回归分析均无统计学显著性。
  • 停药后复发时间更短(汇总 HR 3.63,95%CI 2.58 至 5.10;n=11 项研究,n=3002)。
  • 安慰剂组汇总复发率 36.4%(95%CI 30.8% 至 42.1%;n=28 项研究) vs 抗抑郁药组 16.4%(95%CI 12.6% 至 20.1%;n=28 项研究)。
  • 安慰剂组脱落率更高(汇总 OR 1.31,95%CI 1.06 至 1.63;n=27 项研究)。

关键数值与推荐

  • 复发汇总 OR 3.11(95%CI 2.48 至 3.89),停药组较继续治疗组升高。
  • 复发时间汇总 HR 3.63(95%CI 2.58 至 5.10;n=11 项研究),停药组较继续治疗组缩短。
  • 复发率:安慰剂组 36.4%(95%CI 30.8% 至 42.1%;n=28 项研究) vs 抗抑郁药组 16.4%(95%CI 12.6% 至 20.1%;n=28 项研究)。
  • 脱落汇总 OR 1.31(95%CI 1.06 至 1.63;n=27 项研究),安慰剂组较抗抑郁药组升高。

临床怎么用

  • 作者认为,鉴于焦虑障碍的慢性性,治疗应由长期考虑指导,包括复发率、副作用和患者偏好。
  • 作者指出,缺乏1年之后的证据不应被解释为明确建议在1年后停用抗抑郁药。

局限性

  • 各研究间复发率变异相当大,最可能归因于随访时长不同。
  • 缺乏1年之后的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives To examine the risk of relapse and time to relapse after discontinuation of antidepressants in patients with anxiety disorder who responded to antidepressants, and to explore whether relapse risk is related to type of anxiety disorder, type of antidepressant, mode of discontinuation, duration of treatment and follow-up, comorbidity, and allowance of psychotherapy.Design Systematic review and meta-analyses of relapse prevention trials.Data sources PubMed, Cochrane, Embase, and clinical trial registers (from inception to July 2016).Study selection Eligible studies included patients with anxiety disorder who responded to antidepressants, randomised patients double blind to either continuing antidepressants or switching to placebo, and compared relapse rates or time to relapse.Data extraction Two independent raters selected studies and extracted data. Random effect models were used to estimate odds ratios for relapse, hazard ratios for time to relapse, and relapse prevalence per group. The effect of various categorical and continuous variables was explored with subgroup analyses and meta-regression analyses respectively. Bias was assessed using the Cochrane tool.Results The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year. Across studies, risk of bias was considered low. Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89). Subgroup analyses and meta-regression analyses showed no statistical significance. Time to relapse (n=3002) was shorter when antidepressants were discontinued (summary hazard ratio 3.63, 2.58 to 5.10; n=11 studies). Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group, but prevalence varied considerably across studies, most likely owing to differences in the length of follow-up. Dropout was higher in the placebo group (summary odds ratio 1.31, 1.06 to 1.63; n=27 studies).Conclusions Up to one year of follow-up, discontinuation of antidepressant treatment results in higher relapse rates among responders compared with treatment continuation. The lack of evidence after a one year period should not be interpreted as explicit advice to discontinue antidepressants after one year. Given the chronicity of anxiety disorders, treatment should be directed by long term considerations, including relapse prevalence, side effects, and patients' preferences.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Batelaan NM, Bosman RC, Muntingh A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017. PMID: 28903922. doi:10.1136/bmj.j3927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。